
Opinion|Videos|December 15, 2023
Antibody-Drug Conjugate Safety Profiles in NSCLC
Author(s)Anne S. Tsao, MD, Edward B. Garon, MD, MS
Edward B. Garon, MD, MS, reviews the safety profiles of sacituzumab govitecan and datopotamab deruxtecan in patients with non–small cell lung cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Varegacestat Achieves PFS Gains, Deep Shrinkage of Desmoid Tumors
3
Deep Responses, High MRD Negativity with Teclistamab/Daratumumab in NDMM
4
Deep Proteomic, AI Breast Cancer Detection Test Demonstrates High Performance
5







































